The promise and challenges of antibody drug conjugates for lung cancer

In this video, Sanjay Popat (Consultant Medical Oncologist at the Royal Marsden Hospital, London, UK) discusses the potential of antibody drug conjugates (ADCs) in advancing lung cancer treatment. Watch the full video to learn how ADCs are improving outcomes for NSCLC patients with actionable mutations, emerging ADC approaches such as datopotamab deruxtecan (Dato-DXd) for EGFR-mutant patients, as well as strategies to help improve patient selection, toxicity management and treatment timing. SAVE THE DATE – 17th November 2027 – The 10th Royal Marsden Lung Cancer Symposium. The opinions expressed in this interview are those of the author and do not necessarily...